Key Takeaway: The updated Phase 2 results for Atebimetinib (IMM-1-104) combined with modified Gemcitabine/Nab-Paclitaxel (mGnP) indicate significant improvements in overall survival for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The therapy also shows a favorable tolerability profile, suggesting its potential as a viable treatment option.
Price reaction · baseline $8.08 (2025-09-26 close) · clean, no other IMRX news in the window
day 0 close
-16.5%
day 1
-13.4%
day 3 · peak
-19.2%
Market Sentiment Analysis
POSITIVE FACTORS
Atebimetinib shows extraordinary overall survival in patients.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor
Full Press Release Details
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Frequently Asked Questions
What is Atebimetinib?
Atebimetinib (IMM-1-104) is a drug being studied for treating metastatic pancreatic ductal adenocarcinoma.
What does mGnP stand for?
mGnP stands for modified Gemcitabine/Nab-Paclitaxel, a chemotherapy regimen.
What were the results of the Phase 2 trial?
The updated Phase 2 results showed extraordinary overall survival and favorable tolerability.
Who conducted the Phase 2 trial?
The trial was conducted to evaluate the effectiveness of Atebimetinib combined with mGnP.